Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2029

Conditions
Allogeneic Stem Cell Transplant
Interventions
DRUG

Iron chelation

Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100

DRUG

Potato Resistant Starch

Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily

Trial Locations (1)

48187

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER

NCT06784336 - Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter